Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review
Authors:
- 9 March 2015
- journal article
- review article
- Published by Elsevier in Annals of Oncology
- Vol. 26 (6) , 1081-1090
Abstract
The prevention of chemotherapy-induced nausea and vomiting (CINV) has been revolutionized over the past 25 years. Guideline-based treatment means that vomiting can be prevented in the majority, but not in all patients. Therefore, antiemetic research continues with the goal of optimizing CINV control for all patients. This comprehensive review summarizes the research efforts in this field over the past few years. Emerging from this research are two new antiemetic agents, netupitant/palonosetron, the first antiemetic combination agent and rolapitant, a new NK1RA. In addition, studies have evaluated the benefits of olanzapine and ginger, explored optimal combinations of agents for delayed CINV prevention, confirmed that dexamethasone-sparing regimens are effective, and demonstrated the value of NK1RAs in high-dose chemotherapy settings as well as with certain moderately emetogenic chemotherapies such as carboplatin. Research has also validated the correlation between antiemetic guideline adherence and improved CINV control. Finally, regulatory authorities have utilized extreme caution in retiring some 5-HT3RAs or decreasing their maximum dose.Keywords
This publication has 55 references indexed in Scilit:
- Palonosetron plus single-dose dexamethasone for the prevention of nausea and vomiting in women receiving anthracycline/cyclophosphamide-containing chemotherapy: meta-analysis of individual patient data examining the effect of age on outcome in two phase III trialsSupportive Care in Cancer, 2012
- The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER)Annals of Oncology, 2012
- Ginger (Zingiber officinale) reduces acute chemotherapy-induced nausea: a URCC CCOP study of 576 patientsSupportive Care in Cancer, 2011
- Gabapentin for the prevention of chemotherapy- induced nausea and vomiting: a pilot studySupportive Care in Cancer, 2011
- Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trialSupportive Care in Cancer, 2010
- Antiemetic activity of megestrol acetate in patients receiving chemotherapySupportive Care in Cancer, 2010
- Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomitingJournal of Experimental & Clinical Cancer Research, 2009
- A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centreSupportive Care in Cancer, 2007
- Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity—an updateSupportive Care in Cancer, 2004
- Transferring scientific evidence to oncological practice: a trial on the impact of three different implementation strategies on antiemetic prescriptionsSupportive Care in Cancer, 2004